רווח תפעולי לפני ניכוי פחת: IGC Pharma, Inc. (IGC)

The aggregate EBITDA of IGC Pharma, Inc. (IGC) reflects the high level of physician confidence in the safety of cannabinoid molecules for treating Alzheimer's. The value of 0.00 shows the current profit magnitude supported by partnerships with universities in therapy development. The stability of the R&D core, driven by options and the hiring of compliance experts, minimizes capital risks, as illustrated by the dynamics of this indicator.

Liquidity is critical for IGC Pharma, Inc. (IGC), which focuses on the scientific validation of Alzheimer's disease therapies, to fund clinical stages. This cash operating profit before deductions measures the net cash flow from core activities before depreciation, demonstrating the real resilience of the business model. The dynamics of this metric allow investors to assess the company's speed of adaptation to market stress and the risk of missed opportunities.